AVITA Medical, Inc.

Case Overview
Status: | Status: Investigating |
Ticker: | Ticker: RCEL |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP is investigating potential claims against AVITA Medical, Inc. (“AVITA” or the “Company”) (NASDAQ: RCEL). The investigation concerns whether AVITA and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
On August 7, 2025, Avita released its second quarter 2025 financial results, revealing “a six-month backlog in unpaid provider claims for Recell procedures impacted first-half demand.” The Company explained that contractors assigned by the Centers for Medicare & Medicaid Services to determine pricing of the Company’s wound care product, Recell, “neither assigned a price or assigned an inadequate price and failed to adjudicate claims in a timely manner.” As a result, “claims accumulated from January through June, creating a significant backlog of unpaid claims and inadequately paid claims to providers for Recell procedures. This lack of resolution created uncertainty among providers regarding payment expectations and timelines, which led to a reduction in Recell utilization during the first half of the year.”
On this news, the price of AVITA’s shares declined by $1.13 per share, or approximately 21%, from $5.38 per share on August 7, 2025 to close at $4.25 on August 8, 2025.
On August 7, 2025, Avita released its second quarter 2025 financial results, revealing “a six-month backlog in unpaid provider claims for Recell procedures impacted first-half demand.” The Company explained that contractors assigned by the Centers for Medicare & Medicaid Services to determine pricing of the Company’s wound care product, Recell, “neither assigned a price or assigned an inadequate price and failed to adjudicate claims in a timely manner.” As a result, “claims accumulated from January through June, creating a significant backlog of unpaid claims and inadequately paid claims to providers for Recell procedures. This lack of resolution created uncertainty among providers regarding payment expectations and timelines, which led to a reduction in Recell utilization during the first half of the year.”
On this news, the price of AVITA’s shares declined by $1.13 per share, or approximately 21%, from $5.38 per share on August 7, 2025 to close at $4.25 on August 8, 2025.